The US Food and Drug Administration has approved Astellas Pharma’s Padzeva in combination with Merck’s Keytruda for a type of bladder cancer. In April, the FDA granted accelerated approval for the combination to treat patients with the disease who are not indicated for chemotherapy with the widely used anticancer drug cisplatin.